You are here: Industry Insights > Convidecia

News List

Convidecia™ Phase III Results Published in The Lancet prnasia
December 27, 2021
CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) today announced that The Lancet[1] published its Phase III clinical trial results on the safety and efficacy of its Recombinant Novel Coronavirus Vaccine...
CanSino Biologics Gets OGYÉI GMP Certificate for COVID Vax contractpharma
May 25, 2021
CanSino Biologics Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector, trade name Convidecia), has been granted a Good Manufacturing Practice certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI).
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile prnasia
April 09, 2021
CanSino Biologics Inc. announced that the Instituto de Salud Pública de Chile ("ISP") granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™).
CanSino’s Covid-19 vaccine receives approval in Hungary for emergency use pharmaceutical-technology
March 22, 2021
The Hungarian National Institute of Pharmacy and Nutrition has granted approval for the emergency use of Chinese company CanSino Biologics’ Covid-19 vaccine.
Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization prnasia
February 26, 2021
China National Medical Products Administration (NMPA) announced on February 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector).